Voting is restricted to the twelve members of NACI and occurs through an open process. A quorum of at least two thirds of members is required to authenticate Ibrutinib price a vote. Members who have been absent for all discussions and not able to review all background documentation are not permitted to vote in advance of meetings or calls. The final NACI Advisory Committee Statement, incorporating committee discussion and vote, is circulated by email for approval. After this approval and final review by the NACI Chair and Executive Secretary, the document is sent to the Chief Public Health Officer for final approval. Once edited

and translated into both official languages in Canada (French and English), approved NACI statements are NVP-BGJ398 cell line usually published in the Canada Communicable Disease Report (http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/) and occasionally reprinted in other publications. They are also available on the PHAC website (http://www.phac-aspc.gc.ca/naci-ccni/recs-eng.php), along with the separately posted literature review that supported the development of the Advisory Committee Statement and the recommendations. Recently NACI agreed to use a common template for Advisory Committee Statements. This includes: (1) an introduction (overview of previous NACI

recommendations, national goals for the vaccine-preventable disease/immunization coverage, new evidence triggering the need for a new statement, methodology of the evidence-based review); (2) summary of the disease epidemiology; (3) summary of the vaccine characteristics; (4) recommendations and rationale; (5) research priorities; and (6) surveillance gaps. As noted, national immunization recommendations are developed Ketanserin using an “Analytic Framework for Immunization Recommendations in Canada”

[5]. This framework outlines a number of scientific (e.g. disease burden, vaccine characteristics) and programmatic (e.g. feasibility, acceptability, ethics, cost) factors that should be considered when making decisions regarding immunization programs. NACI considers the scientific factors within this framework, and the Canadian Immunization Committee builds on NACI’s work to additionally consider the factors inherent in program planning and delivery that are outlined in the framework. One challenge that NACI has faced is that it does not explicitly consider economic aspects of vaccine use since this responsibility has been delegated to the Canadian Immunization Committee. Awareness of the cost of vaccines and vaccine programs may be difficult to partition from discussions of the value of a vaccine to individual Canadians or broader populations. NACI may recommend that such factors be considered by local decision-makers or individual healthcare providers when applying NACI guidance.